Headache News and Research

Latest Headache News and Research

Arthritis drug Etanercept clears up symptoms of psoriasis

New research from the United States has found that a drug commonly used to treat arthritis significantly reduces the symptoms of psoriasis in children.

20 Jan 2008

FDA approves Tysabri to treat Crohn's disease

The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.

14 Jan 2008

Seasonal flu levels trigger use of antiviral drugs

The Health Protection Agency has confirmed that the rate at which influenza viruses are now circulating in England has reached the point which triggers the use of antiviral drugs.

11 Jan 2008

Contaminated milk responsible for three deaths and a miscarriage

The latest incident in the United States involving bacteria-contaminated milk has claimed the lives of three elderly men and caused at least one pregnant woman to miscarry since last June.

9 Jan 2008

Dengue seen as potential threat to US public health

A disease most Americans have never heard of could soon become more prevalent if dengue, a flu-like illness that can turn deadly, continues to expand into temperate climates and increase in severity, according to a new commentary by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and David M. Morens, M.D., Fauci's senior scientific advisor.

9 Jan 2008

Experts say far too much is spent on needless indigestion drugs

According to two experts in Britain the National Health Service (NHS) is needlessly spending at least 100m pounds per year on indigestion drugs.

7 Jan 2008

Minorities less likely to receive pain-relieving opioid drugs in ER

Blacks and Hispanics who go to hospital emergency departments in pain are significantly less likely than whites to get pain-relieving opioid drugs, according to a new study funded by the U.S. Department of Health and Human Services.

7 Jan 2008

Cases of meningitis caused by herpes simplex virus set to rise

Viral meningitis is common, but many cases go unreported, say researchers in this week's BMJ.

4 Jan 2008

Use of opioid medications for pain in ERs on the rise, but racial differences in use still exist

In the last 15 years, use of opioid medications to treat patients with pain-related emergency department visits has improved although white patients were more likely to receive opioids than patients of a different race/ethnicity, according to a study in the January 2 issue of JAMA: The Journal of the American Medical Association.

2 Jan 2008

Blacks, Hispanics less likely to get strong pain drugs in emergency rooms

Despite increases in the overall use of opioid drugs to relieve severe pain, black and Hispanic patients remain significantly less likely than whites to receive these pain-relievers in emergency rooms, according to a new national study.

2 Jan 2008

New fast-acting antidote to cyanide poisoning

University of Minnesota Center for Drug Design and Minneapolis VA Medical Center researchers have discovered a new fast-acting antidote to cyanide poisoning.

28 Dec 2007

Pain treatment in the field: Good for soldiers' comfort and better for rebuilding troop strength

Noncombat-related acute and recurrent chronic pain are the leading causes of soldier attrition in modern war, with the return-to-duty rate as low as 2 percent when these soldiers are treated outside the theaters of operation.

18 Dec 2007

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.

10 Dec 2007

Children with sickle cell disease, silent strokes show some relief with blood transfusions

A group of children who have sickle cell disease and who experience silent strokes showed some relief from the silent strokes with blood transfusion therapy, researchers at Washington University School of Medicine in St. Louis have found.

10 Dec 2007

Premature ejaculation drug Dapoxetine submitted for marketing in approval in Europe

Janssen-Cilag companies in Europe have submitted a Marketing Authorisation Application (MAA) for dapoxetine, a treatment for premature ejaculation (PE) in men 18-64 years of age.

10 Dec 2007

Boost for tick disease research

Roman Ganta, a professor of diagnostic medicine and pathobiology at Kansas State University, has been awarded a grant of $1,825,000 by the National Institutes of Health to figure out how to stop the tick-borne bacteria, Ehrlichia chaffeensis, from making animals and people sick.

10 Dec 2007

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

UCB has announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta, administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo.

4 Dec 2007

Approval of Diovan (valsartan) in U.S. for hypertension in children and adolescents

Diovan (valsartan), an angiotensin receptor blocker or ARB, has been approved following a priority review by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure in children and adolescents ages six to 16.

4 Dec 2007

Merck Serono's Cyanokit approved in Europe

Merck Serono, a division of Merck KGaA, announced today that the European Commission has granted marketing authorization for its product Cyanokit (active substance: hydroxocobalamin) for the treatment of known or suspected cyanide poisoning in both adults and the pediatric population.

3 Dec 2007

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

27 Nov 2007

Headache News and Research

Latest Headache News and Research

Arthritis drug Etanercept clears up symptoms of psoriasis

FDA approves Tysabri to treat Crohn's disease

Seasonal flu levels trigger use of antiviral drugs

Contaminated milk responsible for three deaths and a miscarriage

Dengue seen as potential threat to US public health

Experts say far too much is spent on needless indigestion drugs

Minorities less likely to receive pain-relieving opioid drugs in ER

Cases of meningitis caused by herpes simplex virus set to rise

Use of opioid medications for pain in ERs on the rise, but racial differences in use still exist

Blacks, Hispanics less likely to get strong pain drugs in emergency rooms

New fast-acting antidote to cyanide poisoning

Pain treatment in the field: Good for soldiers' comfort and better for rebuilding troop strength

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

Children with sickle cell disease, silent strokes show some relief with blood transfusions

Premature ejaculation drug Dapoxetine submitted for marketing in approval in Europe

Boost for tick disease research

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

Approval of Diovan (valsartan) in U.S. for hypertension in children and adolescents

Merck Serono's Cyanokit approved in Europe

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Headache News and Research

Latest Headache News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in